Overview

This trial is active, not recruiting.

Condition rheumatoid arthritis
Treatment certolizumab pegol
Phase phase 3
Sponsor UCB Pharma SA
Collaborator Parexel
Start date November 2014
End date December 2016
Trial size 347 participants
Trial identifier NCT02319642, CTR20140412, RA0078

Summary

This study will continue to evaluate the safety & efficacy of Certolizumab Pegol (CZP) for 6 months in Chinese subjects with active Rheumatoid Arthritis who participated in RA0044.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W. Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W.
certolizumab pegol Cimzia
Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection

Primary Outcomes

Measure
Percentage of subjects that withdrew due to a Treatment-emergent Adverse Event (TEAE)
time frame: Baseline to the end of observation period (32 weeks)
Percentage of subjects with at least one Treatment-emergent Adverse Event (TEAE)
time frame: Baseline to the end of observation period (32 weeks)
Percentage of subjects with at least one Treatment-emergent Serious Adverse Event (SAE)
time frame: Baseline to the end of observation period (32 weeks)

Secondary Outcomes

Measure
Percentage of subjects meeting the American College of Rheumatology 20 (ACR20) in relation to Baseline
time frame: Week 12
Percentage of subjects meeting the American College of Rheumatology 20 (ACR20) in relation to Baseline
time frame: Week 24
Percentage of subjects meeting the American College of Rheumatology 50 (ACR50) in relation to Baseline
time frame: Week 12
Percentage of subjects meeting the American College of Rheumatology 50 (ACR50) in relation to Baseline
time frame: Week 24
Percentage of subjects meeting the American College of Rheumatology 70 (ACR70) in relation to Baseline
time frame: Week 12
Percentage of subjects meeting the American College of Rheumatology 70 (ACR70) in relation to Baseline
time frame: Week 24
Change from Baseline value in duration of morning stiffness
time frame: Week 12
Change from Baseline value in duration of morning stiffness
time frame: Week 24
Change from Baseline value in tender joint count
time frame: Week 12
Change from Baseline value in tender joint count
time frame: Week 24
Change from Baseline value in swollen joint count
time frame: Week 12
Change from Baseline value in swollen joint count
time frame: Week 24
Change from Baseline value in Physician's Global Assessment of Disease Activity (PhGADA)
time frame: Week 12
Change from Baseline value in Physician's Global Assessment of Disease Activity (PhGADA)
time frame: Week 24
Change from Baseline value in Patient's Assessment of Arthritis Pain (PtAAP)
time frame: Week 12
Change from Baseline value in Patient's Assessment of Arthritis Pain (PtAAP)
time frame: Week 24
Change from Baseline value in Patient's Global Assessment of Disease Activity (PtGADA)
time frame: Week 12
Change from Baseline value in Patient's Global Assessment of Disease Activity (PtGADA)
time frame: Week 24
Change from Baseline value in Health Assessment Questionnaire-Disability Index (HAQ-DI)
time frame: Week 12
Change from Baseline value in Health Assessment Questionnaire-Disability Index (HAQ-DI)
time frame: Week 24
Change from Baseline in Disease Activity Score 28 Joint Count Erythrocyte Sedimentation Rate (DAS28(ESR))
time frame: Week 12
Change from Baseline in Disease Activity Score 28 Joint Count Erythrocyte Sedimentation Rate (DAS28(ESR))
time frame: Week 24
Percentage of subjects who achieve Disease Activity Score 28 Joint Count Erythrocyte Sedimentation Rate (DAS28(ESR)) remission
time frame: Week 24

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - An Institutional Review Board (IRB)/ Independent Ethics Committee (IEC) approved written Informed Consent form (ICF) for RA0078 is signed and dated by the subject or by the parent(s) or legal representative - Subject/ legal representative is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, and medication intake according to the judgment of the Investigator - Subjects must either have: - Completed RA0044 through Week 24, OR - Failed to achieve an ACR20 response at Week 12 (confirmed at Week 14) in RA0044 - Subjects must have complied with the protocol requirements during their participation in RA0044 - Subjects entering RA0078 who have completed RA0044 must have a clear chest x-ray at the Week 24 Completion Visit of RA0044. Subjects who enter RA0078 at Week 16 of the RA0044 study are not required to have a chest x-ray prior to enrollment - Subject is able to continue treatment with Methotrexate (MTX) (with or without folic acid) at a dose deemed appropriate by the Investigator - Female subjects with childbearing potential should have a negative pregnancy test at Entry and should have a medically accepted method of contraception used during the entire duration of the study and for 10 weeks after the last dose of Certolizumab pegol (CZP). Medically accepted methods of contraception are: hormonal contraception for at least 2 cycles prior to Screening, intrauterine device, implant device, diaphragm with spermicide, bilateral tubal ligation, monogamous relationship with vasectomized (for at least 3 months prior to Screening) partner, or using condoms with spermicide gel. Abstinence is not an acceptable method of contraception for the study. Female subjects who are postmenopause for at least 2 years or had undergone a complete hysterectomy, bilateral tubal ligation and/ or bilateral ovariectomy, or have a congenital sterility are considered not of childbearing potential. Male subjects must agree to ensure they use adequate contraception during the study and for at least 10 weeks after the subject receives their last dose of study medication Exclusion Criteria: Rheumatoid Arthritis (RA) disease-related exclusions: - Subjects have a diagnosis of any other inflammatory arthritis eg, psoriatic arthritis or ankylosing spondylitis - Subjects have a secondary, noninflammatory type of arthritis (eg, osteoarthritis or fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of CZP on the subject's primary diagnosis of RA - Subjects have a history of an infected joint prosthesis at any time with that prosthesis still in situ Concomitant medication exclusions - Subjects must be free of the following concomitant medications: - Any biological therapy for RA - Any experimental therapy, within or outside a clinical trial (except RA0044) - Live vaccines Medical history exclusions - Lactating and/or pregnant female subjects - Male subjects with childbearing potential partner(s) and female subjects of childbearing potential who are NOT practicing effective birth control. All female subjects must test negative on a urine pregnancy test before study entry and at each study visit - Subjects with known TB infection, at high risk of acquiring TB infection, or latent TB (LTB) infection (with exception) are excluded - Subjects who had 3 or more infections requiring systemic antibiotics during RA0044 - Subjects with a history of chronic infection, recent serious or life-threatening infection (within 6 months, including herpes zoster), or a current sign or symptom that may indicate an infection (eg, fever, cough) - Subjects with a history or active systemic/ respiratory infection due to fungal, parasitic, or mycotic pathogens including but not limited to histoplasmosis, coccidiosis, paracoccidiosis, pneumocystis, blastomyces, aspergillus, and nontuberculous mycobacteria (NTMB) - Radiographic evidence suggestive of any of these infections is sufficient grounds for exclusion - Subjects at a high risk of infection in the Investigator's opinion (eg, subjects with leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections, and subjects who are permanently bedridden or wheelchair bound) - Subjects with a known positive hepatitis B surface antigen (HBsAg) test and/ or hepatitis C virus antibody (anti-HCV) test result - Subjects with known human immunodeficiency virus (HIV) infection - Subjects with lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease at any time - Subjects with active malignancy of any type - Subjects with a history of blood dyscrasias, eg, leukemia or hemophilia where the blood constituents are abnormal or are present in abnormal quantity. - Subjects with class III or IV congestive heart failure New York Heart Association (NYHA) 1994 - Subjects with suspected or diagnosed demyelinating disease of the central nervous system (eg, multiple sclerosis or optic neuritis) - Subjects with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the subject's participation in the study. Abnormal laboratory parameters that require exclusion of a subject are detailed in protocol - Subjects with an adverse reaction to Percutaneous Endoscopic Gastrostomy (PEG) or a protein medicinal product or known hypersensitivity to any components of the study medication or comparative drugs as stated in this protocol

Additional Information

Official title A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.
Description This study (RA0078) will continue to assess the safety, tolerability, and efficacy of Certolizumab Pegol (CZP) for 6 months as additional medication to methotrexate (MTX) with or without folic acid in Chinese subjects with active Rheumatoid Arthritis (RA) who participated in the main feeder study, RA0044. All subjects will continue to receive their established treatment with MTX with or without folic acid. The dose of MTX may be decreased by the Investigator due to toxicity, but should not be discontinued completely. Concomitant nonsteroidal anti-inflammatory drugs and oral corticosteroids will be permitted. For each subject, the study duration will last a maximum of approximately 32 weeks.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by UCB Pharma.